Sierra Ocean LLC Invests $29,000 in ICON Public Limited (NASDAQ:ICLR)

Sierra Ocean LLC purchased a new position in shares of ICON Public Limited (NASDAQ:ICLR) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 136 shares of the medical research company’s stock, valued at approximately $29,000.

Other institutional investors have also added to or reduced their stakes in the company. Park Place Capital Corp lifted its holdings in ICON Public by 281.4% during the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock worth $47,000 after purchasing an additional 166 shares in the last quarter. GAMMA Investing LLC lifted its holdings in ICON Public by 64.0% during the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after purchasing an additional 169 shares in the last quarter. Whittier Trust Co. of Nevada Inc. lifted its holdings in ICON Public by 23.1% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after purchasing an additional 96 shares in the last quarter. First Horizon Advisors Inc. lifted its holdings in ICON Public by 33.9% during the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after purchasing an additional 151 shares in the last quarter. Finally, Avior Wealth Management LLC lifted its holdings in ICON Public by 76.0% during the 4th quarter. Avior Wealth Management LLC now owns 894 shares of the medical research company’s stock worth $187,000 after purchasing an additional 386 shares in the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

ICON Public Price Performance

ICLR opened at $188.65 on Wednesday. The stock’s 50 day simple moving average is $203.63 and its 200 day simple moving average is $246.83. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. ICON Public Limited has a 1 year low of $181.51 and a 1 year high of $347.72. The firm has a market cap of $15.56 billion, a price-to-earnings ratio of 21.03, a PEG ratio of 1.78 and a beta of 1.19.

Analyst Ratings Changes

Several analysts have weighed in on the company. Truist Financial lowered their price target on ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. William Blair reaffirmed an “outperform” rating on shares of ICON Public in a report on Tuesday, January 14th. JPMorgan Chase & Co. lowered their price target on ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. The Goldman Sachs Group lowered their price target on ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $263.00 price target on shares of ICON Public in a report on Wednesday, January 15th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $283.92.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.